Identification of a regulatory peptide distinct from normal granulocyte-derived hemoregulatory peptide produced by human promyelocytic HL-60 leukemia cells after differentiation induction with retinoic acid.
It has been found that leukemia cells can be induced by various agents [e.g., by retinoic acid (RA)] to mature to a nonproliferative end stage. It has also been found that normal mature granulocytes produce a chalone-like "hemoregulatory peptide (HP)" which seems to be involved in the inhibitory proliferation control of myelopoietic cells. In view of the intended use of maturation induction treatment as an alternative to current antileukemic therapy it appeared to be of interest to know if granulocytes, obtained by RA treatment of the promyelocytic leukemia cell line HL-60, would produce normal HP or if their transformed phenotype would cause production of deviant regulatory peptide(s). It was found that conditioned media from RA-treated HL-60 cells inhibited myeloid proliferation but strongly stimulated the growth of erythroid and lymphoid cells. A low molecular weight thiol-containing peptide was isolated which inhibited colony formation by normal granulocyte-macrophage committed stem cells but unlike HP had no effect on (untreated) HL-60 cells themselves. It was also shown that the HL-60 RA peptide is chemically different from HP in terms of molecular size, electrophoretic mobility, composition, and NH2-terminal sequence, which was determined as glutamine-aspartic acid-proline. It is concluded that differentiated HL-60 cells produce hemoregulatory factor(s) with properties different from those of normal HP. The implication of a possible abnormal regulatory behavior of induced leukemic populations is discussed with respect to leukemia therapy by differentiation induction.
Paukovits
J B
JB
Paukovits
W R
WR
Laerum
O D
OD
D002454:Cell Differentiation / Q000187:drug effects*; D002460:Cell Line; D004920:Erythropoiesis / Q000187:drug effects; D006098:Granulocytes / Q000166:cytology / Q000502:physiology*; D006131:Growth Inhibitors / Q000302:isolation & purification*; D006410:Hematopoiesis; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000473:pathology* / Q000503:physiopathology; D008214:Lymphocytes / Q000166:cytology; D008970:Molecular Weight; D009842:Oligopeptides / Q000502:physiology; D010455:Peptides / Q000302:isolation & purification / Q000502:physiology; D014212:Tretinoin / Q000494:pharmacology*
D006131:Growth Inhibitors; D009842:Oligopeptides; D010455:Peptides; D014212:Tretinoin